Skip to main content
Fig. 1 | Cardiovascular Diabetology

Fig. 1

From: Sitagliptin does not reduce the risk of cardiovascular death or hospitalization for heart failure following myocardial infarction in patients with diabetes: observations from TECOS

Fig. 1

Unadjusted event curves by randomized assignment to sitagliptin or placebo (Kaplan–Meier plots) for the composite outcome of cardiovascular (CV) death or heart failure hospitalization (hHF) (a) and for CV death (b), both occurring after the first within-trial nonfatal myocardial infarction (MI) (defining day 0 on the x-axis). Intention-to-treat analysis

Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840